Comparative Efficacy and Safety of Baricitinib Against Traditional Therapies in Severe Alopecia Areata: A Retrospective Cohort Study
Journal of Cosmetic Dermatology · 2025
DOI: 10.1111/jocd.16666 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Cosmetic Dermatology, 2025. Verfasst von Athanasios J Stefanis und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatovenerology, Third Faculty of Medicine, Charles University and University Hospital Kralovske Vinohrady, Prague, Czech Republic. Hauptthemen laut MEDLINE: Alopecia Areata, Purines, Azetidines, Sulfonamides. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Alopecia areata is a common autoimmune disease which results in reversible hair loss. Janus kinase inhibitors are prescribed for severe alopecia areata with encouraging results. There are no studies comparing the efficacy and safety of Janus kinase inhibitors to traditional treatment options, such as topical immunomodulators and traditional immunosuppressants.
Aims
To retrospectively compare the efficacy and safety of baricitinib, an approved Janus kinase inhibitor, to other treatments for severe AA during a 6‐month treatment period. Materials/Methods We included patients with newly presenting, relapsing or treatment‐resistant alopecia areata with Severity of Alopecia Tool (SALT) score ≥ 50, for the period between July 2021 and July 2023. Medical histories were reviewed and possible side effects were recorded. Primary endpoints were SALT ≤ 20 and SALT ≤ 10 after 6 months of treatment.
Results
Seventy‐five patients (53 females) were divided into three groups: topical immunomodulators (51 patients); baricitinib (19 patients); and a group receiving pulsed intramuscular corticosteroids or traditional immunosuppressants (11 patients). Twenty‐one patients received more than one treatment options within 2 years. After 6 months, the baricitinib group showed superior efficacy with 32% and 26% of patients achieving SALT ≤ 20 and SALT ≤ 10, compared to 12% and 9% in both other groups. Baricitinib demonstrated better secondary outcomes (50% and 90% reduction from initial SALT scores). All treatments exhibited mild‐to‐moderate and expected side effects. Weight gain, which had not been reported in clinical trials for alopecia areata, was observed in three baricitinib‐treated patients.
Conclusion
Baricitinib was superior to traditional treatments for severe alopecia areata after 6 months. Weight gain concerned 16% of patients receiving baricitinib.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatovenerology, Third Faculty of Medicine, Charles University and University Hospital Kralovske Vinohrady, Prague, Czech Republic.
- Value Outcomes, Prague, Czech Republic.
ORCID-Profile: Athanasios J Stefanis
Zitieren
APA
Stefanis, A. J., Dolezal, T., Gkalpakiotis, S., & Arenberger, P. (2025). Comparative Efficacy and Safety of Baricitinib Against Traditional Therapies in Severe Alopecia Areata: A Retrospective Cohort Study. Journal of Cosmetic Dermatology. https://doi.org/10.1111/jocd.16666
Vancouver
Stefanis AJ, Dolezal T, Gkalpakiotis S, Arenberger P. Comparative Efficacy and Safety of Baricitinib Against Traditional Therapies in Severe Alopecia Areata: A Retrospective Cohort Study. Journal of Cosmetic Dermatology. 2025. doi:10.1111/jocd.16666
BibTeX
@article{Stefanis2025,
author = {Stefanis, Athanasios J and Dolezal, Tomas and Gkalpakiotis, Spyridon and Arenberger, Petr},
title = {Comparative Efficacy and Safety of Baricitinib Against Traditional Therapies in Severe Alopecia Areata: A Retrospective Cohort Study},
journal = {Journal of Cosmetic Dermatology},
year = {2025},
doi = {10.1111/jocd.16666}
}
EUVIMED